{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/generalized-anxiety-disorder/prescribing-information/duloxetine-venlafaxine-modified-release/","result":{"pageContext":{"chapter":{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release","depth":2,"htmlHeader":"<!-- begin field a4949546-8797-4eee-a672-9b485414069c --><h2>Duloxetine and venlafaxine modified-release</h2><!-- end field a4949546-8797-4eee-a672-9b485414069c -->","summary":"","htmlStringContent":"<!-- begin item 1d68043d-e8aa-4d9e-b3b6-5d3d32c7534a --><!-- end item 1d68043d-e8aa-4d9e-b3b6-5d3d32c7534a -->","topic":{"id":"a764014a-3ca0-5cd4-899a-93af1654f111","topicId":"135bad2d-5cd6-4df9-b7cf-450677581600","topicName":"Generalized anxiety disorder","slug":"generalized-anxiety-disorder","lastRevised":"Last revised in February 2021","chapters":[{"id":"d7012fbb-d31d-52bd-8499-a790966332f6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ed3d6d57-ce79-58cd-9db0-91ce375231d0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"da5c6fdc-0857-531f-acff-dee7423b2434","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6d8405f1-6ec4-51b4-bc67-ce1dc419f266","slug":"changes","fullItemName":"Changes"},{"id":"dec78b2e-8a69-5c4e-9649-18c59fdff0ff","slug":"update","fullItemName":"Update"}]},{"id":"22e0cf56-e3b6-5744-9fc6-844673300989","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b1e50b04-250b-56d8-b08c-a5e9adc44ecb","slug":"goals","fullItemName":"Goals"},{"id":"62e69cfa-f1e2-54d6-bea8-71f618ecc0f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b044e4ad-382a-5b80-aa6f-0a91d1340216","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b3327928-a8a3-5312-a69d-3d1d69eca670","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a17705aa-783b-5363-8976-4095f0991e87","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"90f89dcc-cd30-59a4-a72e-1b755aec96f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4e9ebfa7-2592-5db9-aa36-cc7c2b32fb70","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"96d96d1d-9961-5dca-a6f4-3327704e9832","slug":"definition","fullItemName":"Definition"},{"id":"736e4407-30b1-5e9c-a715-ca54b10fb58a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"9ca6a146-b065-5743-a95f-2c3ec5008efa","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f4bc4fe6-8936-515a-b07f-8c5d46c63495","slug":"complications","fullItemName":"Complications"},{"id":"71703d6d-00c1-5c15-b2b8-a2c1efc837fb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"8866064e-cc95-5d6d-aeb3-eda0b5463df2","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ed05a1cb-3048-5b62-a242-791415e2e034","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"55866755-f806-55a8-86b7-8e4e99072d8d","fullItemName":"Management","slug":"management","subChapters":[{"id":"93c33dd9-6fcf-5051-9acd-2fd56cad3d31","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"380e5777-c6f3-595b-ac6c-088be521e448","slug":"escitalopram-paroxetine-sertraline","fullItemName":"Escitalopram, paroxetine, and sertraline"},{"id":"e3d86ad6-7dbe-55e6-a0c6-d220d4b12b36","slug":"duloxetine-venlafaxine-modified-release","fullItemName":"Duloxetine and venlafaxine modified-release"},{"id":"96f243eb-7691-57e6-b968-6eeb41bc896d","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"207b91a3-65a7-5bfa-a236-8e796e759e3e","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"5c9792a8-5756-5d84-84c2-8301657b8478","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"795e451d-3583-5146-ab5d-137780924ebc","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c9dc003a-66b8-5907-95b0-90c4ce0ea1d5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5bcc68a1-3691-5684-8f30-113cd9b37910","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7fd23b16-785c-5716-bc47-74a34f4360f5","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c7cfd852-0440-5a24-a57e-2d0dba08a1f2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4c65ec3e-2f85-5406-949d-d124e96e2e26","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d942b94-767d-5df9-82b9-f744d7714cd4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"01b59b3b-cb00-5864-a191-83ef3dd8f60b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"67e06d17-9d90-5f4d-aae5-a2ebaa9ecb3b","slug":"general-information","fullItemName":"General information","depth":3,"htmlHeader":"<!-- begin field 969b1953-5938-4860-be91-a8140172034c --><h3>General information</h3><!-- end field 969b1953-5938-4860-be91-a8140172034c -->","summary":"","htmlStringContent":"<!-- begin item bd60a0e5-909b-498c-973e-a8140171fee3 --><!-- begin field f3c86a4f-f4c6-459a-b20c-a8140172034c --><ul><li><strong>The SNRIs duloxetine and venlafaxine modified-release are both licensed in the UK for the treatment of generalized anxiety disorder (GAD).</strong></li><li>Both have been shown to be effective in the treatment of GAD.</li><li>Choice of SNRI should also take into account the person's preference, and their prior experience of treatment with individual drugs (particularly adherence, effectiveness, side effects, and experience of withdrawal syndrome).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">NICE, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Hoge and Fricchione, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field f3c86a4f-f4c6-459a-b20c-a8140172034c --><!-- end item bd60a0e5-909b-498c-973e-a8140171fee3 -->","subChapters":[]},{"id":"30383265-fe07-5645-8b46-f2e006bf45c3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 689260aa-1d7f-48c4-af1b-a76000d2cf2c --><h3>Contraindications and cautions of duloxetine and venlafaxine modified-release</h3><!-- end field 689260aa-1d7f-48c4-af1b-a76000d2cf2c -->","summary":"","htmlStringContent":"<!-- begin item cc35521b-167e-421b-808e-a76000d2cf7c --><!-- begin field 208f96b1-4fac-4000-bc86-a76000d2cf2c --><ul><li><strong>Do not prescribe SNRIs to people:</strong><ul><li>With uncontrolled hypertension.</li><li>Taking a monoamine oxidase inhibitor (MAOI), or who have recently discontinued an MAOI.</li></ul></li><li><strong>Do not prescribe duloxetine to people with:</strong><ul><li>Liver disease resulting in hepatic impairment.</li><li>Severe renal impairment (creatinine clearance less than 30 mL/min).</li></ul></li><li><strong>Do not prescribe venlafaxine to people with:</strong><ul><li>Conditions associated with high risk of cardiac arrhythmia.</li></ul></li><li><strong>Prescribe an SNRI with caution to people with:</strong><ul><li>Bleeding disorders.<ul><li>Older people or people taking drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin) may also be at risk. Consider prescribing a gastroprotective drug in these circumstances.</li></ul></li><li>Cardiac disease.</li><li>A history of mania.</li><li>Narrow-angle glaucoma or increased intraocular pressure.</li><li>History of seizures.</li><li>Hypertension.<ul><li>For duloxetine, blood pressure monitoring is recommended, especially during the first month of treatment. For people who experience a sustained increase in blood pressure while receiving duloxetine, either dose reduction or gradual discontinuation should be considered.</li><li>For venlafaxine, all people should therefore be screened for high blood pressure and preexisting hypertension should be controlled before initiation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment, and after dose increases.</li><li>With use of duloxetine or venlafaxine, caution should be exercised in people whose underlying conditions might be compromised by increases in blood pressure, such as those with impaired cardiac function.</li></ul></li></ul></li><li><strong>Prescribe duloxetine with caution to:</strong><ul><li>Older people.</li><li>People taking other medicinal products associated with hepatic injury.</li></ul></li><li><strong>Prescribe venlafaxine with caution to people with:</strong><ul><li>Diabetes.</li><li>A recent history of myocardial infarction.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field 208f96b1-4fac-4000-bc86-a76000d2cf2c --><!-- end item cc35521b-167e-421b-808e-a76000d2cf7c -->","subChapters":[]},{"id":"7ff02c49-a4aa-51bf-87ac-f35f7a36c382","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 27e15ea2-ddac-4d5c-98b0-a76000dd6613 --><h3>What adverse effects are associated with duloxetine and venlafaxine modified-release?</h3><!-- end field 27e15ea2-ddac-4d5c-98b0-a76000dd6613 -->","summary":"","htmlStringContent":"<!-- begin item ad117692-e65f-4966-a978-a76000dd6694 --><!-- begin field 3981b87f-ee95-45d4-9ff1-a76000dd6613 --><ul><li><strong>The most common adverse effects include:</strong><ul><li><strong>For duloxetine:</strong> nausea, insomnia, dizziness, dry mouth, somnolence, constipation, anorexia, and abnormal dreams.</li><li><strong>For venlafaxine modified-release: </strong>nausea, insomnia, dry mouth, somnolence, dizziness, constipation, sweating, nervousness, and asthenia. </li></ul></li><li><strong>Other adverse effects of duloxetine and venlafaxine modified-release include:</strong><ul><li><strong>Drowsiness </strong>— may impair performance of skilled tasks such as driving and operating machinery.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">DVLA, 2015</a>].</li></ul></li><li><strong>Hypertension.</strong> <ul><li>Venlafaxine is commonly associated with dose-related increases in blood pressure. Severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience. </li><li>Duloxetine has been associated with increased blood pressure, and clinically significant hypertension in some people. Cases of hypertensive crisis have been reported, especially in people with pre-existing hypertension. </li></ul></li><li><strong>Sexual dysfunction</strong> — this is also a common symptom of generalized anxiety disorder.</li><li><strong>Increased risk of bleeding,</strong> especially in older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li><strong>Hyponatraemia </strong>— risk factors for developing hyponatraemia include a history of hyponatraemia, extreme old age (greater than 80 years of age), female sex, low body weight, diuretics, diabetes mellitus, hypertension, reduced renal function, volume depletion, and chronic obstructive pulmonary disease.<ul><li>Monitor the person for signs and symptoms of hyponatraemia (such as dizziness, lethargy, nausea, confusion, cramps, and seizures).</li></ul></li><li><strong>Increased suicide risk</strong> — this is most likely in younger people (less than 30 years of age) when starting an SNRI.<ul><li>Monitor people carefully during the first few weeks of SNRI treatment; in particular, be alert for signs of suicidal ideation, akathisia, and increased anxiety and agitation. </li></ul></li><li><strong>Discontinuation symptoms</strong> (such as dizziness, sensory disturbances [including paraesthesia], sleep disturbances [including insomnia and intense dreams], agitation or anxiety, nausea and/or vomiting, tremor, and headache).<ul><li>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. </li><li>Generally these symptoms are mild to moderate; however in some people they may be severe.</li><li>They usually occur within the first few days of discontinuing treatment.</li><li>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 – 3 months or more).</li><li>It is therefore advised that an SNRI should be gradually tapered over a period of several weeks or months, according to the person's needs.</li></ul></li><li><strong>Other specific adverse effects of venlafaxine modified release include:</strong><ul><li>Altered glycaemic control in people with diabetes mellitus. Monitor diabetic control in people taking venlafaxine modified release as the doses of insulin or oral anti-diabetic drugs may need to be altered.</li><li>Fatal cardiac arrhythmias have been reported, especially in overdose. The balance of risks and benefits should therefore be considered before prescribing venlafaxine to people at high risk of serious cardiac arrhythmia.</li><li>Takotsubo or stress cardiomyopathy.</li></ul></li><li><strong>Duloxetine use has also been associated with </strong><strong>liver injury</strong>, including severe elevations of liver enzymes (>10-times upper limit of normal), hepatitis, and jaundice. This is most likely during the first months of treatment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2020b</a>]</p><!-- end field 3981b87f-ee95-45d4-9ff1-a76000dd6613 --><!-- end item ad117692-e65f-4966-a978-a76000dd6694 -->","subChapters":[]},{"id":"cf2a7464-61e8-5a53-a0e9-0a0b377954fb","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 2b05e14f-e61f-4c7f-86d7-a76000ddb1c1 --><h3>What key drug interactions with duloxetine or venlafaxine modified-release should I be aware of?</h3><!-- end field 2b05e14f-e61f-4c7f-86d7-a76000ddb1c1 -->","summary":"","htmlStringContent":"<!-- begin item eaabf95b-6579-4d5f-ab44-a76000ddb293 --><!-- begin field 8d729d81-85e1-467a-87fd-a76000ddb1c1 --><ul><li><strong>Key drug interactions with SNRIs as a class include:</strong><ul><li>MAOIs — CNS effects of SSRIs increased by MAOIs (risk of serious toxicity).</li><li>5HT<sub>3</sub>- receptor antagonists, dapoxetine, SSRIs, St John's Wort, tramadol — risk of increased serotonergic effects.<ul><li>The manufacturer of dapoxetine advises SNRIs should not be started until 1 week after stopping dapoxetine, and to avoid dapoxetine for 2 weeks after stopping SNRIs.</li></ul></li><li>Aspirin and NSAIDs — increased risk of bleeding.</li><li>Warfarin — increases in INR values have been reported when SNRIs were co-administered with warfarin.<ul><li>Consider frequent monitoring of the INR. </li></ul></li></ul></li><li><strong>In addition, for duloxetine:</strong><ul><li>Amitriptyline, clomipramine, moclobemide — risk of increased serotonergic effects.</li><li>Ciprofloxacin — avoid concomitant use. Metabolism of duloxetine is inhibited by ciprofloxacin.</li></ul></li><li><strong>In addition, for venlafaxine:</strong><ul><li>Amiodarone, erythromycin, moxifloxacin, sotalol — avoid concomitant use due to risk of ventricular arrhythmias. <ul><li><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment has been stopped.</li></ul></li><li>Bupropion — plasma concentration of venlafaxine increased by bupropion.</li><li>Entacapone  — caution with venlafaxine advised by the manufacturer of entacapone.</li><li>Haloperidol — venlafaxine increases plasma concentration of haloperidol.</li><li>Lithium, mirtazapine — possible increased serotonergic effects.</li><li>Selegiline — increased risk of hypertension and CNS excitation. Selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>]</p><!-- end field 8d729d81-85e1-467a-87fd-a76000ddb1c1 --><!-- end item eaabf95b-6579-4d5f-ab44-a76000ddb293 -->","subChapters":[]},{"id":"b5c42865-6d15-5fc1-b7df-b38ebf99c5d3","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field b6578086-66ae-4a3b-93b5-a76000ddecf7 --><h3>What dose of duloxetine or venlafaxine modified-release should I use and how should I titrate the dose?</h3><!-- end field b6578086-66ae-4a3b-93b5-a76000ddecf7 -->","summary":"","htmlStringContent":"<!-- begin item 92e622f7-6c1c-426e-a3d6-a76000ddecf0 --><!-- begin field 762d9e60-ae3f-4a25-a006-a76000ddecf7 --><ul><li><strong>For duloxetine:</strong> prescribe a starting dose of 30 mg a day. Increase to 60 mg daily if necessary; the maximum licensed dose for generalized anxiety disorder is 120 mg daily.</li><li><strong>For venlafaxine modified-release: </strong>prescribe a starting dose of 75 mg a day. Increase gradually if necessary at intervals of 2 weeks up to a maximum dose of 225 mg a day.</li><li><strong>If changing between anxiolytic medications:</strong><ul><li>When switching from an SSRI to an SNRI, cautious cross tapering using a low dose SNRI is generally recommended. However, a more rapid switch to duloxetine 60 mg/day is possible.</li><li>When switching from an SNRI to an SSRI, cross taper cautiously, starting with low dose SSRI.</li><li>For information on switching to and from other groups of antidepressants, see the section on switching antidepressants in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/generalized-anxiety-disorder/references/\">Taylor, 2015</a>]</p><!-- end field 762d9e60-ae3f-4a25-a006-a76000ddecf7 --><!-- end item 92e622f7-6c1c-426e-a3d6-a76000ddecf0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}